IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Trial record 1 of 1 for:
"Favism"
A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency
This study has been completed.
Sponsor:
Walter Reed Army Institute of Research (WRAIR)
Information provided by:
Walter Reed Army Institute of Research (WRAIR)
ClinicalTrials.gov Identifier:
NCT00076323
First received: January 20, 2004
Last updated: July 26, 2010
Last verified: July 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples.
| Condition | Intervention |
|---|---|
| Glucosephosphate Dehydrogenase Deficiency Favism | Drug: Primaquine |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | A New Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency |
Resource links provided by NLM:
Genetics Home Reference related topics:
glucose-6-phosphate dehydrogenase deficiency
MedlinePlus related topics:
G6PD Deficiency
Genetic and Rare Diseases Information Center resources:
Glucose-6-phosphate Dehydrogenase Deficiency
U.S. FDA Resources
Further study details as provided by Walter Reed Army Institute of Research (WRAIR):
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion:
- Normal clinical evaluation
- Willing and able to make all scheduled visits
Exclusion:
- pregnant or planning pregnancy
- Have taken any anti-malarial medication in past month
- Positive blood tests for HIV and specific types of hepatitis
- Allergic to primaquine
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00076323
Please refer to this study by its ClinicalTrials.gov identifier: NCT00076323
Locations
| United States, Maryland | |
| Walter Reed Army Institute of Research | |
| Silver Spring, Maryland, United States, 20910 | |
Sponsors and Collaborators
Walter Reed Army Institute of Research (WRAIR)
Investigators
| Principal Investigator: | Shon A Remich | WRAIR, Experimental Therapeutics |
More Information
Additional Information:
| ClinicalTrials.gov Identifier: | NCT00076323 History of Changes |
| Other Study ID Numbers: |
WRAIR 992 G6PD |
| Study First Received: | January 20, 2004 |
| Last Updated: | July 26, 2010 |
Keywords provided by Walter Reed Army Institute of Research (WRAIR):
|
G6PD Favism G6PD Deficiency |
hemolysis drug reaction drug-induced hemolysis |
Additional relevant MeSH terms:
|
Favism Glucosephosphate Dehydrogenase Deficiency Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Genetic Diseases, Inborn Carbohydrate Metabolism, Inborn Errors Metabolism, Inborn Errors Metabolic Diseases |
Foodborne Diseases Poisoning Chemically-Induced Disorders Plant Poisoning Primaquine Antimalarials Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents |
ClinicalTrials.gov processed this record on July 13, 2017